OBJECTIVE: To evaluate the safety and efficacy of FK506-based dual therapy and CsA-based triple therapy for immunosuppression after liver transplantation. METHODS: The literature about the randomized controlled trials (RCT) on FK506 and CsA for immunosuppression after liver transplantation was retrieved for analysis using RevMan 5.0 software. RESULTS: A total of 7 RCTs were included; 3 were considered as high quality of RCT, 4 as moderate quality. The results of Meta-analysis of FK506-based dual therapy indicated the patients’ survival rate (RR=1.06, 95%CI=0.77～1.45,P=0.72), grafts’ survival rate (RR=0.99, 95%CI=0.76～1.29,P=0.92), infection rate(RR=0.98, 95%CI=0.60～1.58,P=0.93)and incidence of neurotoxicity (RR=0.59, 95%CI=0.32～1.07,P=0.08)was not significantly different. The incidence of acute rejection in CsA group was lower than in FK506 group (RR=1.57, 95%CI=1.23～2.01,P=0.000 3). CONCLUSION: The curative efficacy of FK506 group is not different from that of CsA group in respect of rate of patient/graft, infection but increase the incidence of acute rejection. Because CsA can increase incidence of neurotoxicity, it is suggestion to treat patients of nervous systerm disease with FK506.

Objective: To analyze the compatibility taboo of polyene phosphatidyl choline injection with several kinds of commonly used clinical drugs.Methods: The medical literatures on the compatibility taboos of polyene phosphatidyl choline injection with several commonly used drugs were retrieved and statistically analyzed.Results: After the compatibility of polyene phosphatidyl choline injection with vitamin C, raceanisodamine injection, doxofylline and sodium chloride injection,ambroxol hydrochloride injection,ondansetron hydrochloride injection and the other commonly used drugs, physical and chemical reactions happened in varying degrees.Conclusion: Polyene phosphatidyl choline injection has compatibility taboos with a variety of commonly used drugs.